Literature DB >> 22168428

Inhibitory effects of dopamine on spinal synaptic transmission via dopamine D1-like receptors in neonatal rats.

K Kawamoto1, K Otsuguro, M Ishizuka, S Ito.   

Abstract

BACKGROUND AND
PURPOSE: Dopamine released from the endings of descending dopaminergic nerve fibres in the spinal cord may be involved in modulating functions such as locomotion and nociception. Here, we examined the effects of dopamine on spinal synaptic transmissions in rats. EXPERIMENTAL APPROACH: Spinal reflex potentials, monosynaptic reflex potential (MSR) and slow ventral root potential (sVRP), were measured in the isolated spinal cord of the neonatal rat. Dopamine release was measured by HPLC. KEY
RESULTS: Dopamine at lower concentrations (<1 µM) depressed sVRP, which is a C fibre-evoked polysynaptic response and believed to reflect nociceptive transmission. At higher concentrations (>1 µM), in addition to a potent sVRP depression, dopamine depolarized baseline potential and slightly depressed MSR. Depression of sVRP by dopamine was partially reversed by dopamine D(1) -like but not by D(2) -like receptor antagonists. SKF83959 and SKF81297, D(1) -like receptor agonists, and methamphetamine, an endogenous dopamine releaser, also caused the inhibition of sVRP. Methamphetamine also depressed MSR, which was inhibited by ketanserin, a 5-HT(2A/2C) receptor antagonist. Methamphetamine induced the release of dopamine and 5-HT from spinal cords, indicating that the release of endogenous dopamine and 5-HT depresses sVRP and MSR respectively. CONCLUSION AND IMPLICATIONS: These results suggested that dopamine at lower concentrations preferentially inhibited sVRP, which is mediated via dopamine D(1) -like and other unidentified receptors. The dopamine-evoked depression is involved in modulating the spinal functions by the descending dopaminergic pathways.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22168428      PMCID: PMC3417505          DOI: 10.1111/j.1476-5381.2011.01815.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  62 in total

1.  D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function.

Authors:  B Levant; K E McCarson
Journal:  Neurosci Lett       Date:  2001-04-27       Impact factor: 3.046

Review 2.  Descending control of pain.

Authors:  Mark J Millan
Journal:  Prog Neurobiol       Date:  2002-04       Impact factor: 11.685

3.  7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists.

Authors:  T Witt; F J Hock; J Lehmann
Journal:  J Med Chem       Date:  2000-05-18       Impact factor: 7.446

4.  Heterogeneity of neuronal nicotinic acetylcholine receptors in 5-HT-containing chemoreceptor cells of the chicken aorta.

Authors:  S Ito; T Ohta; Y Kasai; K Yonekubo; Y Nakazato
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors.

Authors:  M J Millan; A Newman-Tancredi; Y Quentric; D Cussac
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

6.  Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300.

Authors:  S A Rostom; A M Farghaly; F S Soliman; M M el-Semary; S Elz; J Lehmann
Journal:  Arch Pharm (Weinheim)       Date:  2001-07       Impact factor: 3.751

7.  Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons.

Authors:  J K Seamans; N Gorelova; D Durstewitz; C R Yang
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

8.  Effects of dopaminergic agents on carrageenan hyperalgesia after intrathecal administration to rats.

Authors:  X Gao; Y Zhang; G Wu
Journal:  Eur J Pharmacol       Date:  2001-04-20       Impact factor: 4.432

9.  Effects of opioid receptor and alpha2-adrenoceptor agonists on slow ventral root potentials and on capsaicin and formalin tests in neonatal rats.

Authors:  Ken-ichi Otsuguro; Sumiko Yasutake; Toshio Ohta; Shigeo Ito
Journal:  Brain Res Dev Brain Res       Date:  2005-08-08

10.  Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands.

Authors:  Hussein El-Subbagh; Thomas Wittig; Michael Decker; Sigurd Elz; Martin Nieger; Jochen Lehmann
Journal:  Arch Pharm (Weinheim)       Date:  2002-11       Impact factor: 3.751

View more
  2 in total

1.  The activation of D2 and D3 receptor subtypes inhibits pathways mediating primary afferent depolarization (PAD) in the mouse spinal cord.

Authors:  Jonathan J Milla-Cruz; Elvia Mena-Avila; Jorge R Calvo; Shawn Hochman; Carlos M Villalón; Jorge N Quevedo
Journal:  Neurosci Lett       Date:  2020-07-16       Impact factor: 3.046

2.  Antidepressant-like effects of cinnamamide derivative M2 via D2 receptors in the mouse medial prefrontal cortex.

Authors:  Yan-Xin Che; Xiao-Yan Jin; Rong-Hua Xiao; Ming Zhang; Xiao-Hui Ma; Fei Guo; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2022-01-25       Impact factor: 7.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.